Turna Ray has been covering the personalized medicine and molecular diagnostics industries for GenomeWeb since 2006. She closely tracks the evolving regulatory, reimbursement, and business environment for precision medicine products.
During an "Investor Day" presentation, company executives presented plans for growing test volumes, increasing market share, and expanding access to underserved populations.
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.
The college wants genetic counselors to work with doctors when ordering genetic tests, but not all medical geneticists agree the stance is good for patients.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
Williams v Quest/Athena struck a nerve with the genetic testing community by probing what the standard of care is and ought to be for variant classification.
Palmetto Cease-and-Desist Letter to Reimbursement Expert Raises Questions About Pricing Transparency
As government lab spending grows, the Medicare contractor has barred access to a coding and pricing file obtained via FOIA claiming it holds business secrets.
The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.
Results from the PROMPT registry presented at ASCO showed that 10 to 15 percent of women with variants in genes not linked to ovarian cancer had oophorectomies.
In an interview, Marilyn Li and Douglas Stewart discuss why ACMG has put forth points that doctors and labs should consider when presumed germline findings crop up in tumor testing.